Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows (Unaudited)

v2.4.0.8
Consolidated Statements of Cash Flows (Unaudited) (USD $)
 9 Months Ended
Aug. 31, 2014
Aug. 31, 2013
Statement of Cash Flows [Abstract]    
Net Income $ 849,457 $ 194,782
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization expense 287,010 300,311
Abandonment of patents 25,649 378,837
Loss on sale of property and equipment 0 44,428
Compensatory element of stock options 255,380 225,177
Provision for doubtful accounts 913,235 583,182
Equity in losses of affiliate 242,318 115,475
Changes in assets and liabilities:    
Accounts receivable (1,527,397) (319,521)
Notes receivable 550,782  
Prepaid expenses and other current assets 105,045 136,719
Deposits and other assets, net 52,628 28,400
Accounts payable (156,306) 34,929
Accrued expenses (657,576) (1,232,887)
Deferred revenue 371,511 353,993
Net cash provided by operating activities 1,311,736 843,825
Cash flows from investing activities:    
Release of restricted cash held in escrow 764,045 1,156,030
Purchases of property and equipment (93,478) (239,381)
Purchases of marketable securities and other investments, net (84,753) (18,480)
Investments in patents 0 (34,525)
Investment in affiliate (150,000)  
Net cash provided by investing activities 435,814 863,644
Cash flows from financing activities:    
Treasury stock purchases (2,294,631) (672,066)
Proceeds from the exercise of stock options 70,902 14,950
Net cash used in financing activities (2,223,729) (657,116)
(Decrease) increase in cash and cash equivalents (476,179) 1,050,353
Cash and cash equivalents - beginning of period 3,925,156 2,677,382
Cash and cash equivalents - end of period 3,448,977 3,727,735
Supplemental non-cash disclosure:    
Disposition of Cryo-Cell common stock held by Saneron, increase in investment $ 74,764